SCHEMBL5545843

SCHEMBL5545843

CCCCNC(=O)OCC(COCC)OC(=O)NCCCC

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.54
ALOX15 P16050 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12451130 0.87 EPHX1 (0.58) ACHEALOX15
SCHEMBL19197809 0.86 ALOX15 (0.39) ACHEALOX15
SCHEMBL16325240 0.84 ACHE (0.50) ACHEALOX15
SCHEMBL1537776 0.84 ACHE (0.54) ACHEALOX15
SCHEMBL16298778 0.83 EPHX1 (0.53) ACHEALOX15
SCHEMBL12451127 0.81 EPHX1 (0.54) ACHEALOX15
SCHEMBL12451129 0.81 EPHX1 (0.54) ACHEALOX15
SCHEMBL12451125 0.81 EPHX1 (0.54) ACHEALOX15
SCHEMBL12451126 0.81 EPHX1 (0.54) ACHEALOX15
SCHEMBL7745030 0.80 PRKCA (0.54) ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226004-A1 FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION JPMORGAN CHASE BANK, N.A. 2024-07-11 US disclosed
US-20180071231-A1 FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION KINDEVA DRUG DELIVERY L.P. 2018-03-15 US disclosed
US-20170292445-A1 INTERNAL COMBUSTION ENGINE COMPONENTS WITH ANTI-FOULING PROPERTIES AND METHODS OF MAKING SAME 3M INNOVATIVE PROPERTIES COMPANY 2017-10-12 US disclosed
US-8815325-B2 Medicinal inhalation device 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-08-26 US disclosed
US-8808786-B2 Medicinal inhalation devices and components thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-08-19 US disclosed
US-20130229378-A1 OPTICAL DEVICE SURFACE TREATMENT PROCESS AND SMUDGE-RESISTANT ARTICLE PRODUCED THEREBY 3M INNOVATIVE PROPERTIES COMPANY 2013-09-05 US disclosed
US-20130220177-A1 SURFACE TREATMENT PROCESS, COMPOSITION FOR USE THEREIN, AND TREATED ARTICLE 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-29 US disclosed
US-20130213395-A1 MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-22 US disclosed
US-8430097-B2 Medicinal inhalation devices and components thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-04-30 US disclosed
US-20120295119-A1 METHOD OF MAKING COATED METAL ARTICLES 3M INNOVATIVE PROPERTIES COMPANY 2012-11-22 US disclosed
US-20120103330-A1 MEDICINAL INHALATION DEVICE 3M INNOVATIVE PROPERTIES COMPANY 2012-05-03 US disclosed
US-20100263667-A1 MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF 3M INNOVATIVE PROPERTIES COMPANY 2010-10-21 US disclosed
US-20100242958-A1 MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226004-A1 FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION MCOLN3, SYMPK, ADRB2 ACHE 879/4885ALOX15 428/4885
US-20180071231-A1 FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION ADRB2, MCOLN3, ADRB1 ACHE 286/4885ALOX15 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.